slides · global inventory
Traction
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 10,471
Current window 6,421-6,450
Pages 350
Rows per page 30
Slide type
6,421-6,450 of 10,471
11
The slide demonstrates how 23andMe's genetic data can rescue or refine clinical trial results by identifying biomarkers that stratify patient response.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Logic Chain1 hit
18
The slide uses a process flow to illustrate the speed of development, supported by heatmaps and a bar chart showing adverse event profiles.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
25
The chart uses a swimmer plot format to visualize patient-level treatment duration, dose escalation, and response status.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
26
Includes before-and-after CT scan imagery for two lesion types.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
12
The chart highlights a positive trend in US comps, reaching 2% in Q3 2023.a.k.a. Brands | Investor Presentation Deck | 14 slides · a.k.a. Brands
Pitch deck Investor relations Beat · The BreakthroughLoop · Cost Of Inaction1 hit
13
The slide uses two line charts to demonstrate financial health improvement.a.k.a. Brands | Investor Presentation Deck | 14 slides · a.k.a. Brands
Pitch deck Investor relations Beat · The BreakthroughLoop · Quick Win Big Bet1 hit
11
Data presented at EASL 2022, AASLD 2022, GHS 2023.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
12
Data presented at EASL 2022. Shows dual-axis line charts for viral load/ALT and bar charts for T-cell frequency.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
15
Data presented at EASL 2023. Includes both a summary table of mean changes and individual patient trajectory charts.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
18
Data presented at AASLD 2023. Shows ELISpot results for T cell responses and HBsAg levels.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
19
The slide details a specific licensing deal with Qilu Pharmaceutical, including financial terms and geographic scope.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
10
Includes study design parameters (NST002) and key clinical outcomes.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
16
The slide highlights clinical trial safety data for PrimeC.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Before After1 hit
17
The slide highlights a 37.4% reduction in disease progression with statistical significance (p=0.03) in the per-protocol population, while noting a 29% reduction in the ITT analysis.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Before After1 hit
19
The chart visualizes the reduction in points lost, highlighting a 3.22 point difference (p=0.03).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
20
The slide uses a human body diagram to categorize ALS symptoms and bar charts to show the reduction in point loss (slower disease progression) for each category.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
21
The chart highlights a 17.2% attenuation in the decline of SVC score for the PrimeC group compared to placebo.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
25
The slide presents clinical biomarker data (Aβ40, Aβ42, Tau, pTau, PgJ2) comparing control vs AD groups, analyzed via Mann-Whitney U test.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
31
The chart shows a clear divergence between the treatment and placebo groups over time, with error bars indicating variability.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
32
The chart highlights a 13.3% difference at the 180-day mark.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
09
The slide demonstrates superior tumor growth inhibition by NXP800 compared to Cisplatin in both resistant and sensitive models.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
Includes a patient MRI, a schematic of the PDX study design, a line chart showing tumor volume over time, and photographic evidence of tumor size reduction.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · Market Size1 hit
11
The slide presents preclinical efficacy data for NXP800 in specific genetic subtypes of endometrial cancer.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · Market Size1 hit
19
The charts show tumor regression in NXP900 treated groups versus tumor growth in control groups over 27 days.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
22
Clinical trial identifier NCT05873686 is provided.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
04
The slide uses a 3x3 grid of metric cards to present operational and financial performance.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · Traction1 hit
13
The slide uses a logo-grid approach to demonstrate market breadth and brand partnerships.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Loop · Golden Circle1 hit
16
The slide uses a color-coded three-pillar structure to present key financial KPIs.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · FinancialsLoop · Golden Circle1 hit
17
The slide uses a consistent color-coded bar chart format to demonstrate financial performance trends.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · FinancialsLoop · Golden Circle1 hit
18
2020 data is omitted due to COVID-19.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Loop · Golden Circle1 hit